Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 201

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 201
---
 by each
class of shareholders. If the transaction would have been approved but for the separate approval of each class or the exclusion of the
votes of certain shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of
the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the value of the parties
to the merger and the consideration offered to the shareholders. Pursuant to the Companies Law, if a merger is with a company’s
controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to
the same special majority approval that governs all extraordinary transactions with controlling shareholders (as described above under
“Board Practices — Fiduciary duties and approval of specified related party transactions under Israeli law.”).

Under the Companies Law,
each merging company must send a copy of the proposed merger plan to its secured creditors. Unsecured creditors are entitled to receive
notice of the merger pursuant to regulations promulgated under the Companies Law. Upon the request of a creditor of either party to the
proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of
the merger, the surviving company will be unable to satisfy the obligations the target company. The court may further give instructions
to secure the rights of creditors.

In addition, a merger may
not be completed unless at least 50 days have passed from the date that a proposal for approval of the merger was filed with the Israeli
Registrar of Companies and 30 days from the date that shareholder approval of both merging companies was obtained.

Anti-takeover measures

The Companies Law allows
us to create and issue shares having rights different from those attached to our Ordinary Shares, including shares providing certain
preferred rights with respect to voting, distributions or other matters and shares having preemptive rights. As of the closing of this
offering, no preferred shares will be authorized under our amended and restated articles of association. In the future, if we do authorize,
create and issue a specific class of preferred shares, such class of shares, depending on the specific rights that may be attached to
it, may have the ability to frustrate or prevent a takeover or otherwise prevent our shareholders from realizing a potential premium
over the market value of their Ordinary Shares. The authorization and designation of a class of preferred shares will require an amendment
to our amended and rest